Impact of BR-3 mutation on B-cell subsets in the BM and spleen
| Tissue subset* . | A/J . | A/WySnJ . | ||
|---|---|---|---|---|
| %† . | No.‡ (× 10−6) . | %† . | No.‡ (× 10−6) . | |
| BM | ||||
| CD19+ | 26.4 (1.1) | 84.5 (3.6) | 15.3 (3.1) | 49.0 (10.1) |
| Fr E, CD23− | 3.77 (0.41) | 13.7 (2.0) | 4.52 (0.9) | 11.7 (2.8) |
| Fr E, CD23+ | 1.12 (0.13) | 4.13 (0.5) | 0.59 (0.06) | 1.53 (0.3) |
| Spleen | ||||
| CD19+ | 54.5 (2.2) | 44.4 (0.6) | 13.6 (1.1) | 5.8 (0.3) |
| T1 | 0.26 (0.02) | 0.22 (0.01) | 0.09 (0.13) | 0.04 (0.004) |
| T2 | 0.31 (0.28) | 0.30 (0.03) | 0.03 (0.003) | 0.01 (0.002) |
| T3 | 0.32 (0.04) | 0.30 (0.02) | 0.05 (0.01) | 0.03 (0.006) |
| FOL | 41.7 (1.1) | 33.3 (1.0) | 5.28 (1.3) | 2.17 (0.44) |
| Tissue subset* . | A/J . | A/WySnJ . | ||
|---|---|---|---|---|
| %† . | No.‡ (× 10−6) . | %† . | No.‡ (× 10−6) . | |
| BM | ||||
| CD19+ | 26.4 (1.1) | 84.5 (3.6) | 15.3 (3.1) | 49.0 (10.1) |
| Fr E, CD23− | 3.77 (0.41) | 13.7 (2.0) | 4.52 (0.9) | 11.7 (2.8) |
| Fr E, CD23+ | 1.12 (0.13) | 4.13 (0.5) | 0.59 (0.06) | 1.53 (0.3) |
| Spleen | ||||
| CD19+ | 54.5 (2.2) | 44.4 (0.6) | 13.6 (1.1) | 5.8 (0.3) |
| T1 | 0.26 (0.02) | 0.22 (0.01) | 0.09 (0.13) | 0.04 (0.004) |
| T2 | 0.31 (0.28) | 0.30 (0.03) | 0.03 (0.003) | 0.01 (0.002) |
| T3 | 0.32 (0.04) | 0.30 (0.02) | 0.05 (0.01) | 0.03 (0.006) |
| FOL | 41.7 (1.1) | 33.3 (1.0) | 5.28 (1.3) | 2.17 (0.44) |
B-cell subsets in the indicated 8-week-old mice were defined as follows and as illustrated in Figure 1A: Fr E, B220+ sIgM+ AA4+/− CD23+/−; T1, B220+ AA4+ CD23− sIgMhigh; T2, B220+ AA4+ CD23+ sIgMhigh; T3, B220+ AA4+ CD23+ sIgMlow; FOL, B220+ AA4− CD23+ sIgMlow.
Mean percent of all viable BM or spleen cells derived from 3 (A/J) and 4 (A/WySnJ) mice per group.
Absolute numbers were calculated by multiplying the total cell numbers by the percent cells within each population.
Absolute numbers of BM cells within each gate were calculated using the previously described estimate for the total number of BM cells per adult mouse of 3.2 × 108 (see “Materials and methods”).25